Systemic Heparin use in Upper Extremity Arteriovenous access maintenance for dialysis: A meta-analysis of randomized studies (Kei, 2026)

Rego RA; Cetinel E; Dagostin AF; Labib M; Shun Kei H; Habiyambere GI; Madera D

Annals of Vascular Surgery 2026, Jan 13

Available online at this link

A significant proportion of arteriovenous fistulas (AVFs) and grafts for hemodialysis fail due to early thrombosis, necessitating reintervention. The role of systemic heparinization in improving perioperative patency remains uncertain. This meta-analysis aims to evaluate the efficacy and safety of perioperative systemic heparin on the patency of upper-limb vascular access creations (fistulas or grafts placement).

We searched PubMed, Embase, and Cochrane databases for randomized trials comparing heparinization versus standard care in adults undergoing arm AVF or graft placement. Data were pooled using a random-effects model to calculate odds ratios (ORs) with 95% confidence intervals (CIs). Heterogeneity was assessed using I2 statistics. All statistical analyses were conducted using Review Manager 5.4.

Six studies comprising 1,265 patients were included, of whom 731 (58%) underwent heparinization. Systemic heparinization significantly reduced the odds of early patency loss compared to standard care (OR: 0.58; 95% CI: 0.37–0.92; P = 0.02; I2 = 14%). However, heparin was associated with an increased risk of bleeding complications (OR: 4.24; 95% CI: 1.13–15.9; P = 0.13; I2 = 47%).

Perioperative systemic heparinization significantly improves early patency rates for hemodialysis vascular access in adults undergoing arm fistulization or graft placement; however, there is a risk of increased bleeding events. Heparin may be considered a viable preventive strategy against early thrombosis, though its use should be balanced against individual patient bleeding risk and surgical considerations.